What is the Familial Adenomatous Polyposis Treatment Market?
Currently, the treatment paradigm for FAP includes surgical intervention such as Colectomy with ileorectal anastomosis (IRA), Restorative proctocolectomy with the formation of the ileoanal pouch (RPC), and Total proctocolectomy with ileoanal anastomosis (TPC).
However, various potential chemopreventive agents that are understudies include Nonsteroidal anti-inflammatory drugs (NSAIDs), ursodeoxycholic acid, statins, difluoro methyl ornithine (DFMO), and certain combinational therapies. The Total Market Size of FAP will include the Familial Adenomatous Polyposis Market Size of both the potential upcoming therapies along with Current treatment regimens in the seven Major Markets.
Key considerations in the management of a patient with FAP involve surgical intervention. The rationale is to remove the colon or colon and rectum to substantially reduce the risk of colorectal cancer. Thus, the aim is to undertake surgery before cancer develops.
Chemopreventive strategies have also been studied in FAP patients to delay the development of adenomas in the upper and lower gastrointestinal tract, as well as to prevent recurrence of adenomas in the retained rectum of patients after surgery.
The surgical options in FAP are minimally invasive and involve Colectomy with ileorectal anastomosis (IRA), in which the rectum is left in place, Restorative proctocolectomy with the formation of the ileoanal pouch (RPC), in which the colon and rectum are removed and an opening (ileostomy) is created, usually on the right side of your abdomen and Total proctocolectomy with ileoanal anastomosis (TPC) (also called J-pouch surgery), in which the colon and rectum are removed and a part of the small intestine is attached to the rectum.
Chemoprevention is the use of pharmaceutical or natural agents to prevent or delay the development of cancer in healthy patients. Three main roles can be played by the chemopreventive agents in patients with FAP, to delay prophylactic colectomy, to prevent cancer development in the retained rectum in patients after colectomy with IRA, and to prevent cancer development in the upper gastrointestinal tract, especially the duodenum.
Nonsteroidal anti-inflammatory drugs (NSAIDs), ursodeoxycholic acid, statins, difluoro-methyl ornithine (DFMO), and various dietary supplements have been studied as potential treatment agents.
An all-inclusive account of both the current and emerging therapies for FAP, along with the assessment of new therapies, will have an impact on the current treatment landscape.
Original Source:- Familial Adenomatous Polyposis Market Research Report
Comments